ResMed Inc. (ASX:RMD)
Australia
· Delayed Price · Currency is AUD | Market Cap | 53.37B |
| Revenue (ttm) | 7.96B |
| Net Income (ttm) | 2.02B |
| Shares Out | n/a |
| EPS (ttm) | 13.69 |
| PE Ratio | 26.45 |
| Forward PE | n/a |
| Dividend | 0.47 (1.30%) |
| Ex-Dividend Date | Feb 12, 2025 |
| Volume | 1,049,817 |
| Average Volume | 1,202,402 |
| Open | 36.52 |
| Previous Close | 36.77 |
| Day's Range | 36.25 - 36.52 |
| 52-Week Range | 26.64 - 40.75 |
| Beta | 0.70 |
| RSI | 32.20 |
| Earnings Date | Apr 25, 2025 |
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on de... [Read more]
Financial Performance
In 2024, ResMed's revenue was $4.69 billion, an increase of 10.95% compared to the previous year's $4.22 billion. Earnings were $1.02 billion, an increase of 13.75%.
Financial numbers in USD Financial StatementsNews
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD)
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD)
SECURE Act 2.0: What Every Retiree Needs to Know About RMD Changes
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. SECURE 2.0 has significant changes that could help streng...
Jan De Witte joins GHO Capital as Operating Partner
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February...
ResMed Close To Joining Very Elite Stock Group
ResMed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
Stock Of The Day: Different Ways To Profit From SoundHound
Shares of SoundHound AI, Inc. (NASDAQ: SOUN) are making a nice move higher Tuesday. Some analysts believe that this is due to a report that suggests institutions make up more than 30% of the company'...
Stock Of The Day: Trading The Range In ResMed
ResMed Inc. (NYSE: RMD) shares are consolidating on Monday. This follows Friday's decline of more than 8%. The sell-off was driven by a disappointing earnings report . Traders are waiting to see if R...
Stock Of The Day: Trading The Range In ResMed
ResMed Inc. RMD shares are consolidating on Monday. This follows Friday's decline of more than 8%.
ResMed: Snoozers Can Be Winners
ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for profit-taking despite long-term growth.
ResMed Inc (RMD) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
ResMed Inc (RMD) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments Propel Performance
ResMed targets 59-60% gross margins and expanded global reach for AirSense 11
ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript
ResMed: Digital Health Drives Q2 Growth
ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability.
ResMed beats earnings forecasts on sleep device demand
The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.
Sleep device giant ResMed says Trump tariffs will boost profits
The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.
Resmed declares fiscal Q2 dividend of $0.53
ResMed's (RMD) board of directors declared an unchanged quarterly dividend of $0.53 per share on Thursday. Read more here.
ResMed beats quarterly profit estimates on demand for sleep disorder devices
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
ResMed Inc (RMD) Reports Strong Q2 2025 Financial Results
ResMed Inc (RMD) Reports Strong Q2 2025 Financial Results
ResMed, In A Buy Zone, Stays Flat After Handily Beating Earnings Views
ResMed stock was roughly flat late Thursday after the CPAP maker beat earnings expectations. Shares are in a buy zone.
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025
Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ASX 200 LIVE: ASX to reset record as BHP, Fortescue rise; Origin lowers LNG guidance; Apple profit rises
Miners lead ASX to new record; Magellan sell-off extends. Netwealth CFO exits; Origin drops LNG forecasts; Aus CEO exits Resmed; Lendlease to sell Capella.
ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)
ResMed exec splashes $24m on Westfield heirs’ mansion
Sydney luxury property: Westfield heirs sell $24m Bellevue Hill mansion to ResMed exec
Here are Thursday's biggest analyst calls: Nvidia, Tesla, Amazon, Philip Morris, AMD, ResMed, First Solar, Disney, UPS & more
Here are the biggest calls on Wall Street on Thursday.
Top 50 High Quality Dividend Growth Stocks - January 2025
I track 50 high-quality dividend stocks, updating their valuations daily to identify Strong Buy, Buy, Hold, and Trim opportunities based on historical free cash flow trends. Using my quality score and...